补体介导肾脏疾病:替代途径在肾小球炎症中的作用
本文综述补体介导肾脏疾病(CMKDs)中替代补体途径的作用。替代途径通过放大补体激活驱动肾小球炎症和组织损伤,临床前模型、组织学关联及替代途径抑制疗效均支持其参与。靶向替代途径的新型补体抑制剂正在临床开发中,可能比传统免疫抑制或终端途径抑制更精准有效。
要点
- 替代途径放大补体激活,是CMKDs肾小球炎症的关键驱动因素。
- 临床前模型、组织学损伤关联及抑制疗效均支持替代途径参与。
- 靶向替代途径的新药正在开发,可能更精准且耐受性更好。
核心结论
- 替代补体途径在CMKDs的肾小球炎症中起核心放大作用,靶向该途径是有前景的治疗策略。
研究设计与样本
- 综述,总结临床前体内模型、组织学关联及替代途径抑制的临床证据。
主要发现
- 替代途径放大补体激活,驱动肾小球炎症和组织损伤,与疾病严重程度相关。
- 替代途径抑制在CMKDs患者中显示疗效。
临床怎么用
- 靶向替代途径的补体抑制剂可能比传统免疫抑制或终端途径抑制更精准、耐受性更好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Complement-mediated kidney diseases (CMKDs) comprise a diverse group of rare disorders characterized by the activation of the complement system, leading to glomerular inflammation, kidney injury, and in some cases, kidney failure. Although the contribution of complement activation to disease pathogenesis varies across CMKDs, the alternative complement pathway appears to play a pivotal role in driving inflammation and tissue damage in the kidney by amplifying complement activation, regardless of the initiating complement pathway. A growing body of evidence links the alternative pathway with glomerular inflammation in CMKDs, including key mechanistic insights from preclinical in vivo models, the association of alternative pathway components with histologic kidney injury and disease severity, and the efficacy of alternative pathway inhibition in patients with these disorders. With an improved understanding of the mechanisms of alternative pathway overactivation in CMKDs, many novel complement inhibitors targeting the alternative pathway are in clinical development for the management of CMKDs, potentially offering a more precise, better-tolerated, and effective approach than conventional immunosuppressive agents or therapeutics that provide broader inhibition of the common terminal complement pathway. This review summarizes the role of the alternative pathway in the pathogenesis of CMKDs and provides evidence supporting its involvement in glomerular inflammation. In addition, we provide a future perspective on the principles guiding the treatment of glomerular inflammation with therapies that target the alternative pathway.
引用
- Barratt J, Garred P, Lafayette RA, et al. Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation. Kidney Int Rep. 2025. PMID: 41550519. doi:10.1016/j.ekir.2025.11.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。